Evista and Neuropathy - peripheral - a phase IV clinical study of FDA data

Summary:

Neuropathy - peripheral is reported as a side effect among people who take Evista (raloxifene hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Neurontin, and have Convulsion.

The phase IV clinical study analyzes which people have Neuropathy - peripheral when taking Evista. It is created by eHealthMe based on reports of 25,442 people who have side effects when taking Evista from the FDA, and is updated regularly.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

What is Neuropathy - peripheral?

Neuropathy - peripheral (surface nerve damage) is found to be associated with 660 drugs and 1,007 conditions by eHealthMe. Check the latest studies of Neuropathy - peripheral.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 27, 2026

25,442 people reported to have side effects when taking Evista.
Among them, 32 people (0.13%) have Neuropathy - peripheral.

Could Evista cause Neuropathy - peripheral?

Among these 32 people:

How long have people been on Evista when they have Neuropathy - peripheral? *

What is the gender of people who have Neuropathy - peripheral when taking Evista? *

female: 96.88 %
male: 3.12 %

What is the age of people who have Neuropathy - peripheral when taking Evista? *

What are other drugs people take besides Evista? *

What are other side effects people have besides Neuropathy - peripheral? *

Fall: 9 people, 28.12%
Weight Increased: 6 people, 18.75%
Joint Pain: 6 people, 18.75%
Fatigue (feeling of tiredness): 5 people, 15.62%
Feeling Abnormal: 5 people, 15.62%
Difficulty In Walking: 5 people, 15.62%
Injection Site Haemorrhage (bleeding from injection site): 5 people, 15.62%
Nausea (feeling of having an urge to vomit): 4 people, 12.50%
Headache (pain in head): 4 people, 12.50%
Hot Flush (sudden feelings of heat): 4 people, 12.50%

What are the existing conditions these people have? *

High Blood Cholesterol: 2 people, 6.25%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 6.25%
Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 1 person, 3.12%
Pain: 1 person, 3.12%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 3.12%
Multiple Myeloma (cancer of the plasma cells): 1 person, 3.12%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 3.12%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 3.12%
Diabetes: 1 person, 3.12%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Evista and have Neuropathy - peripheral?

- Check whether Neuropathy - peripheral is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Evista:

Evista (25,891 reports)

Browse all side effects of Evista:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neuropathy - peripheral:

Neuropathy - peripheral (660 drugs)

Browse all the conditions that are associated with Neuropathy - peripheral:

Neuropathy - peripheral (1,007 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride (the active ingredients of Evista) and Evista (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.